Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
With a disproportionate number of black cisgender women in the U.S. becoming HIV positive, researchers at The University of Texas Health Science Center at Houston are sharing critical health information through an atypical venue: the emergency room.
Data from a new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases – found fewer new cases of hepatitis C infection (commonly called HCV), despite very high rates of other sexually-transmitted infections, in HIV-negative men who have sex with men who take pre-exposure prophylaxis (PrEP) treatments.
In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.
The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.
A clinical trial has begun to examine the safety and use of two HIV prevention tools--oral pre-exposure prophylaxis and a vaginal ring--in adolescent girls and young women in southern Africa.
AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.
New research presented at the HIV Drug Therapy Conference in Glasgow today shows that pre-exposure prophylaxis could be given to millions of people worldwide with no increased risk of safety issues during treatment.
The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants.
New guidelines for Canada have been published in the Canadian Medical Association Journal online this week that outline the use of new anti-HIV medications among high risk populations who are at risk of contracting HIV from getting the dreaded infection. These new guidelines aim to provide the clinicians with resources and support he added.
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, and could help to prevent up to one in four cases of HIV, according to a study published in The Lancet Infectious Diseases journal.
For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.
After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.
The HIV Prevention Trials Network, which includes McGovern Medical School at The University of Texas Health Science Center at Houston, has launched a study to evaluate whether a new injectable medication can work as well as an existing oral pill to safely protect against HIV among men who have sex with men (MSM) and transgender women (TGW) who have sex with men.
A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.
The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today.
The drug combination emtricitabine/tenofovir alafenamide is approved in combination with other antiviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1).
A Houston Methodist research team received a nearly $4 million grant to test a transcutaneously refillable implant that administers pre-exposure prophylaxis drugs to subjects at risk of HIV-exposure.
Researchers are edging ever closer to discovering the perfect combination of drugs and drug delivery system that will stop the sexual transmission of HIV.
A team led by researchers from UCSF and Yale has found that half of people newly infected with HIV experience neurologic issues. These neurologic findings are generally not severe and usually resolve after participants started anti-retroviral therapy.
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.